Immunophenotypic features and EBV status of 96 cases with IVLBCL
| . | Total series . | CD5− . | CD5+ . |
|---|---|---|---|
| No. of patients | 96 | 60 | 36 |
| CD10 | 12/96 (13) | 7/60 (12) | 5/36 (14) |
| CD19 | 35/41 (85) | 18/21 (86) | 17/20 (85) |
| CD20 | 92/96 (96) | 56/60 (93) | 36/36 (100) |
| CD23 | 3/70 (4) | 2/45 (4) | 1/25 (4) |
| CD79a | 49/49 (100) | 30/30 (100) | 19/19 (100) |
| Bcl-2 | 52/57 (91) | 33/37 (89) | 19/20 (95) |
| Bcl-6* | 16/62 (26) | 9/36 (25) | 7/26 (27) |
| MUM1/IRF4† | 58/61 (95) | 34/36 (94) | 24/25 (96) |
| Cyclin D1 | 0/51 (0) | 0/32 (0) | 0/19 (0) |
| κ chain | 20/28 (71) | 11/16 (69) | 9/12 (75) |
| λ chain | 5/28 (18) | 3/16 (19) | 2/12 (17) |
| EBERs-ISH | 0/59 (0) | 0/40 (0) | 0/19 (0) |
| . | Total series . | CD5− . | CD5+ . |
|---|---|---|---|
| No. of patients | 96 | 60 | 36 |
| CD10 | 12/96 (13) | 7/60 (12) | 5/36 (14) |
| CD19 | 35/41 (85) | 18/21 (86) | 17/20 (85) |
| CD20 | 92/96 (96) | 56/60 (93) | 36/36 (100) |
| CD23 | 3/70 (4) | 2/45 (4) | 1/25 (4) |
| CD79a | 49/49 (100) | 30/30 (100) | 19/19 (100) |
| Bcl-2 | 52/57 (91) | 33/37 (89) | 19/20 (95) |
| Bcl-6* | 16/62 (26) | 9/36 (25) | 7/26 (27) |
| MUM1/IRF4† | 58/61 (95) | 34/36 (94) | 24/25 (96) |
| Cyclin D1 | 0/51 (0) | 0/32 (0) | 0/19 (0) |
| κ chain | 20/28 (71) | 11/16 (69) | 9/12 (75) |
| λ chain | 5/28 (18) | 3/16 (19) | 2/12 (17) |
| EBERs-ISH | 0/59 (0) | 0/40 (0) | 0/19 (0) |
Values before and after slash indicate numbers of positive and evaluable patients, respectively. Values in parentheses are percentages.
EBERs-ISH indicates in situ hybridization using EBV-encoded small nuclear early region oligonucleotides.
All of the Bcl-6+ cases showed a partial and weak reaction in 10% to 50% of the tumor cells.
All 3 MUM1/IRF4− cases showed a negative reaction to CD10 and Bcl-6.